NEOGENOMICS INC

Listed Company

NEOCIK 0001077183NasdaqLarge AcceleratedServices-Testing LaboratoriesNevadaFY ends Dec 31

Period

FY 2025

Revenue

—

Net Income

$-108.03M

Total Assets

$1.36B

Equity

$836.56M

Shares Out

130.21M

Op. Cash Flow

$5.23M

NEO$14.60+117.59% · past yearDBEQ Basic

Daily closing prices

Business

NeoGenomics provides oncology diagnostic testing and consultative services through a network of CAP-accredited and CLIA-certified laboratories in the United States and United Kingdom. Its service offerings include cytogenetics, FISH, flow cytometry, immunohistochemistry, molecular residual disease testing, NGS molecular testing, morphologic analysis, and interpretation by specialized pathologists and molecular experts. The company serves community-based pathology practices, hospital pathology labs, reference laboratories, academic centers, and pharmaceutical companies through both technical and professional component services, pharmaceutical development support, and oncology data solutions.

Summary from 10-K filed 2026-02-17

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
NET REVENUE	727	661	592	510	484
COST OF REVENUE	413	370	347	322	297
GROSS MARGIN	314	290	245	188	187
General and administrative	273	260	243	243	221
Research and development	37	31	27	30	22
Sales and marketing	92	85	71	67	63
Restructuring charges	0	7	11	5	0
Impairment charges (Note 3 and Note 7)	28	0	0	—	—
Total operating expenses	430	382	352	346	306
LOSS FROM OPERATIONS	−116	−92	−108	−158	−119
Interest income	−9	−18	−17	−6	—
Interest expense	4	7	7	8	—
Other (income) expense, net	−296,000	379,000	−644,000	213,000	499,000
Loss before taxes	−110	−81	−97	−159	−15
Income tax benefit	−2	−2	−9	−15	−7
NET LOSS	−108	−79	−88	−144	−8
Basic (in dollars per share)	−0.84	−0.62	−0.7	−1.16	−0.07
Diluted (in dollars per share)	−0.84	−0.62	−0.7	−1.16	−0.07
Basic (in shares)	128	127	126	124	120
Diluted (in shares)	128	127	126	124	120

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	160	367	342	263	317
Marketable securities, at fair value	0	20	73	175	199
Accounts receivable, net	159	151	131	120	112
Inventories	29	27	24	24	23
Prepaid assets	21	20	18	15	12
Other current assets	7	12	8	8	8
Total current assets	376	596	597	605	682
Property and equipment (net of accumulated depreciation of $209,057 and $189,990, respectively)	85	94	92	102	109
Operating lease right-of-use assets	78	80	92	96	102
Intangible assets, net	287	340	373	408	442
Goodwill	524	523	523	523	527
Other assets	9	6	5	5	7
Total non-current assets	984	1,042	1,084	1,135	1,188
Total assets	1,360	1,638	1,681	1,740	1,870
Accounts payable	23	22	20	21	18
Accrued compensation	48	62	53	40	38
Accrued expenses and other liabilities	12	13	15	15	18
Current portion of operating lease liabilities	5	3	6	7	7
Current portion of convertible senior notes, net	0	201	0	—	—
Contract Liabilities	851,000	409,000	2	8	5
Total current liabilities	88	301	96	90	87
Operating lease liabilities	63	61	68	69	72
Convertible senior notes, net	342	340	538	535	532
Deferred income tax liabilities, net	18	22	24	35	55
Other long-term liabilities	12	12	13	13	14
Total long-term liabilities	435	434	643	652	674
Total liabilities	523	736	740	742	762
Commitments and contingencies (Note 15)	—	—	—	—	—
Common stock, $0.001 par value, (250,000,000 shares authorized; 128,989,152 and 128,145,333 shares issued and outstanding, respectively)	129,000	128,000	127,000	127,000	124,000
Additional paid-in capital	1,270	1,228	1,190	1,161	1,124
Accumulated other comprehensive income (loss)	4,000	−206,000	−2	−4	−638,000
Accumulated deficit	−434	−326	−247	−159	−15
Total stockholders equity	837	902	942	998	1,108
Total liabilities and stockholders' equity	1,360	1,638	1,681	1,740	1,870

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Depreciation	36	39	37	35	30
Amortization of intangibles	32	33	35	34	23
Stock-based compensation	41	33	25	25	22
Non-cash operating lease expense	7	9	9	10	9
Amortization of convertible debt discount	2	3	3	3	3
Amortization of debt issuance costs	87,000	189,000	185,000	182,000	178,000
Loss (gain) on disposal of assets, net	31,000	−49,000	292,000	3	606,000
Impairment of long-lived assets	0	500,000	2	718,000	0
Other adjustments	−323,000	178,000	186,000	2	2
Accounts receivable, net	−6	−19	−12	−8	−5
Inventories	−2	−3	−454,000	−1	2
Prepaid and other assets	2	−7	−3	−1	−2
Operating lease liabilities	−2	−6	−8	−9	−8
Deferred income tax liabilities, net	−3	−3	−11	−16	−6
Accrued compensation	−16	9	13	2	12
Accounts payable, accrued and other liabilities	−5	−4	−5	958,000	8
Net cash provided by (used in) operating activities	5	7	−2	−66	−27
Purchases of marketable securities	0	0	−7	−98	−197
Proceeds from maturities of marketable securities	20	54	112	117	—
Purchases of property and equipment	−27	−41	−29	−31	−64
Proceeds from assets held for sale, net of closing costs	2	0	0	—	—
Business acquisitions, net of cash acquired	−6	0	0	0	−419
Purchase of convertible note	−500,000	0	0	—	—
Purchase of equity securities	−500,000	0	0	—	—
Net cash (used in) provided by investing activities	−12	13	77	517,000	−632
Repayment of equipment financing obligations	0	0	−70,000	−758,000	−3
Issuance of common stock, net	962,000	5	5	13	15
Repayment of convertible debt	−201	0	0	—	—
Net cash (used in) provided by financing activities	−200	5	5	12	725
Net change in cash and cash equivalents	−207	25	79	−54	66
Interest paid	2	4	3	3	3
Federal	30,000	−194,000	0	—	—
Income taxes paid, net:	515,000	207,000	175,000	180,000	148,000
Purchases of property and equipment included in accounts payable	2	1	610,000	2	1
Right-of-use assets obtained in exchange for operating lease liabilities	6	617,000	8	—	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Frequently asked questions

What is NEOGENOMICS INC's CIK number?

NEOGENOMICS INC's SEC CIK number is 0001077183 (1077183). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find NEOGENOMICS INC's SEC filings?

All of NEOGENOMICS INC's EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

When did NEOGENOMICS INC last report earnings?

NEOGENOMICS INC (NEO) most recently filed an earnings 8-K with the SEC on Apr 28, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001077183-26-000022). This is NEOGENOMICS INC's most recent earnings filing of record — not a forecast of its next earnings date.

What is NEOGENOMICS INC's most recent earnings 8-K?

NEOGENOMICS INC's latest earnings 8-K (Item 2.02) was filed Apr 28, 2026 under accession 0001077183-26-000022. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.

View NEOGENOMICS INC's latest earnings 8-K →
Look up any company's CIK number →